| scholarly article | Q13442814 |
| P50 | author | Eric Winer | Q16887072 |
| Edith A. Perez | Q18389345 | ||
| James N Ingle | Q89668737 | ||
| George Sledge | Q92594250 | ||
| Clifford A Hudis | Q92892082 | ||
| Vera J Suman | Q96186734 | ||
| Julie R Gralow | Q101346124 | ||
| Silvana Martino | Q114412398 | ||
| P2093 | author name string | Bernard J Gersh | |
| Nancy E Davidson | |||
| Peter A Kaufman | |||
| Allan S Jaffe | |||
| Shaker R Dakhil | |||
| Richard J Rodeheffer | |||
| Karen A Gelmon | |||
| P2860 | cites work | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Cardiac dysfunction in the trastuzumab clinical trials experience | Q28204298 | ||
| Risk factors for doxorubicin-induced congestive heart failure | Q28328220 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Trastuzumab-associated cardiotoxicity | Q34867708 | ||
| Early and delayed clinical cardiotoxicity of doxorubicin | Q42225832 | ||
| Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. | Q44362100 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre | Q61624905 | ||
| Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group | Q77347398 | ||
| HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial | Q79816337 | ||
| Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial | Q80558275 | ||
| Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment | Q81419131 | ||
| Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity | Q81698731 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | doxorubicin | Q18936 |
| breast cancer | Q128581 | ||
| trastuzumab | Q412616 | ||
| paclitaxel | Q423762 | ||
| P304 | page(s) | 1231-1238 | |
| P577 | publication date | 2008-02-04 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial | |
| P478 | volume | 26 |
| Q37158620 | A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients |
| Q38029563 | A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study). |
| Q35693076 | A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group |
| Q90101142 | A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study |
| Q36100606 | A retrospective review of the metabolic syndrome in women diagnosed with breast cancer and correlation with estrogen receptor |
| Q27025860 | Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care? |
| Q36098713 | Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis |
| Q34023749 | Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines |
| Q40806854 | Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice |
| Q37458836 | Adjuvant systemic therapy for older adults with early-stage breast cancer |
| Q26741523 | Adjuvant systemic therapy in older women with breast cancer |
| Q38253136 | Adjuvant systemic treatment for elderly breast cancer patients; addressing safety concerns. |
| Q37376169 | Adjuvant targeted therapy in early breast cancer. |
| Q35051256 | Adjuvant therapy for women over age 65 with breast cancer |
| Q37571648 | Adjuvant therapy of triple negative breast cancer |
| Q55181611 | Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. |
| Q35989963 | Advances in first-line treatment for patients with HER-2+ metastatic breast cancer |
| Q37815614 | Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer |
| Q39263199 | Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany |
| Q39117949 | Assessment of concomitant versus sequential trastuzumab on radiation-induced cardiovascular toxicity |
| Q37392175 | Assessment of health status in elderly patients with cancer |
| Q54192533 | Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer. |
| Q88188525 | Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials |
| Q36900970 | Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study |
| Q95942184 | Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a Position Statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European So |
| Q37046302 | Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer |
| Q33976440 | Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice |
| Q35490056 | Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations |
| Q36887091 | Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. |
| Q38791220 | Cardiac Complications of HER2-Targeted Therapies in Breast Cancer |
| Q37163787 | Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer |
| Q40353199 | Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. |
| Q35990409 | Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 - a prospective study |
| Q35039549 | Cardiac dysfunction after cancer treatment |
| Q44868340 | Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998–2005 |
| Q28081385 | Cardiac risk in the treatment of breast cancer: assessment and management |
| Q34975825 | Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients |
| Q84781418 | Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer |
| Q36936807 | Cardiac side effects of trastuzumab in breast cancer patients - single centere experiences |
| Q44490665 | Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer |
| Q38091377 | Cardiac toxicity of anticancer agents |
| Q26741182 | Cardiac toxicity of trastuzumab in elderly patients with breast cancer |
| Q37471532 | Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? |
| Q28068290 | Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management |
| Q57108766 | Cardio-oncology: protecting the heart from curative breast cancer treatment |
| Q38242641 | Cardiomyopathy associated with cancer therapy |
| Q37735969 | Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab |
| Q48008904 | Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms? |
| Q42373758 | Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies. |
| Q36884357 | Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium |
| Q38508938 | Cardiotoxicity due to Chemotherapy: the Role of Biomarkers |
| Q89160743 | Cardiotoxicity of Novel Targeted Chemotherapeutic Agents |
| Q38473331 | Cardiotoxicity of anticancer treatments |
| Q37788952 | Cardiotoxicity of anticancer treatments: what the cardiologist needs to know |
| Q37165488 | Cardiotoxicity profile of trastuzumab |
| Q40034267 | Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study |
| Q50045986 | Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. |
| Q36721511 | Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged Sword |
| Q35584686 | Cardiovascular complications of breast cancer therapy in older adults |
| Q38338228 | Cardiovascular prevention in the cancer survivor |
| Q34630349 | Cardiovascular toxicities from systemic breast cancer therapy |
| Q33949465 | Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors |
| Q37547962 | Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer |
| Q38580452 | Chemotherapy-induced cardiomyopathy |
| Q37172361 | Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab |
| Q38522989 | Comorbidities and Their Management: Potential Impact on Breast Cancer Outcomes |
| Q36637777 | Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer |
| Q50720975 | Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series. |
| Q54490269 | Delay to formalin fixation 'cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistry. |
| Q34255916 | Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics |
| Q53075042 | Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography. |
| Q38168792 | Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis. |
| Q36875361 | Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction |
| Q36875372 | Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea |
| Q37206247 | EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy |
| Q57142283 | Early breast cancer |
| Q35584539 | Early breast cancer in the older woman |
| Q39653595 | Early breast cancer in the older woman. |
| Q58616457 | Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study |
| Q36980191 | Effects of radiation on the epidermal growth factor receptor pathway in the heart |
| Q36210992 | Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial |
| Q35742760 | Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer |
| Q36824869 | Efficacy, safety and administration timing of trastuzumab in human epidermal growth factor receptor 2 positive breast cancer patients: A meta-analysis |
| Q39844710 | Estimating recurrences prevented from using trastuzumab in HER-2/neu-positive adjuvant breast cancer in the United States. |
| Q47116524 | Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer |
| Q33964848 | Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. |
| Q35428376 | Geriatric assessment in older patients with breast cancer |
| Q37521326 | Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). |
| Q34328064 | HER2 signaling pathway and trastuzumab cardiotoxicity |
| Q34062418 | HER2 status and breast cancer therapy: recent advances |
| Q37355586 | HER2-positive male breast cancer: an update. |
| Q83864121 | Helical tomotherapy in patients with breast cancer and complex treatment volumes |
| Q84382705 | High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers |
| Q92064459 | Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands |
| Q26824542 | How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer |
| Q36958226 | Human epidermal growth factor receptor 2-positive breast cancer: which cytotoxic agent best complements trastuzumab's efficacy in vitro? |
| Q99545835 | Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study |
| Q37315173 | Impact of cardiovascular comorbidity on ovarian cancer mortality |
| Q49961375 | Incidence, Diagnosis, and Treatment of Cardiac Toxicity from Trastuzumab in Patients with Breast Cancer |
| Q26774597 | Infracentimetric HER-2 positive breast tumours-review of the literature |
| Q38218014 | Is there any cumulative dose for trastuzumab? |
| Q37338235 | Jumping higher: is it still possible? The ALTTO trial challenge |
| Q84903909 | Late effects of adjuvant systemic therapies in women diagnosed with breast cancer at a young age |
| Q35878469 | Lifestyle interventions for cardiovascular risk reduction in women with breast cancer |
| Q28083233 | Long term side effects of adjuvant chemotherapy in patients with early breast cancer |
| Q37166431 | Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial |
| Q45071046 | Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Pa |
| Q51715669 | Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study. |
| Q35819307 | Managing high-risk breast cancer |
| Q30439608 | Mechanisms of Anthracycline Cardiotoxicity and Strategies to Decrease Cardiac Damage |
| Q83602951 | Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better |
| Q43180234 | Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall |
| Q57106864 | Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs |
| Q36085651 | Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis. |
| Q64252887 | On-chip combined radiotherapy and chemotherapy testing on soft-tissue sarcoma spheroids to study cell death using flow cytometry and clonogenic assay |
| Q35583779 | Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider |
| Q35239634 | Optimal systemic therapy for early breast cancer in women: a clinical practice guideline |
| Q34035460 | Optimizing the management of HER2-positive early breast cancer: the clinical reality |
| Q38065341 | Overview of breast cancer treatment and reconstruction for primary care providers. |
| Q26744675 | Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity |
| Q37644025 | Phage-Enabled Nanomedicine: From Probes to Therapeutics in Precision Medicine |
| Q35205385 | Pharmacoeconomic considerations in the treatment of breast cancer |
| Q53398198 | Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01. |
| Q36097717 | Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group |
| Q36432099 | Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198) |
| Q33930241 | Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab |
| Q34189102 | Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity |
| Q49037203 | Prevention and Treatment of Cardiac Dysfunction in Breast Cancer Survivors |
| Q37785387 | Prevention and management of major side effects of targeted agents in breast cancer |
| Q60930844 | Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution |
| Q64904632 | Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. |
| Q36718403 | RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. |
| Q48142619 | Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer. |
| Q33427353 | Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. |
| Q92713306 | Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer |
| Q37208730 | Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer. |
| Q33862786 | Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update |
| Q30663382 | Relationship between clinical data and gene expression in the HER2/ErbB2-dependent signaling pathway in patients with acute heart failure. |
| Q37800698 | Risk of cardiac dysfunction with trastuzumab in breast cancer patients: A meta-analysis |
| Q36207305 | Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study |
| Q35880224 | Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer |
| Q34779675 | Risk of trastuzumab-related cardiotoxicity in early breast cancer patients: a prospective observational study |
| Q35687465 | Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer |
| Q37355762 | Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer |
| Q37401837 | Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer |
| Q37355370 | Role of trastuzumab in the management of HER2-positive metastatic breast cancer. |
| Q39212340 | SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab |
| Q54593797 | Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study. |
| Q36851424 | Senior adult oncology |
| Q35609706 | Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer |
| Q36339698 | Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epider |
| Q41682625 | Special Issues in Older Women with Breast Cancer |
| Q38876363 | Supportive Care in Older Adults with Cancer: Across the Continuum |
| Q36821958 | Systemic cancer therapy: achievements and challenges that lie ahead |
| Q28260063 | Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline |
| Q36245324 | Targeted therapies in breast cancer: are heart and vessels also being targeted? |
| Q42571051 | Targeted therapy in HER2-positive breast cancer |
| Q34272044 | Targeting HER2 in breast cancer: overview of long-term experience |
| Q37205811 | Targeting the human epidermal growth factor receptor 2 pathway in breast cancer |
| Q35948882 | The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis |
| Q40420807 | The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study |
| Q37992829 | The adjuvant treatment of HER2-positive breast cancer |
| Q37696505 | The cardiac safety of trastuzumab in the treatment of breast cancer |
| Q38296287 | The development of dose-dense adjuvant chemotherapy |
| Q30659496 | The impact of comorbidity on Health-Related Quality of Life among cancer survivors: analyses of data from the PROFILES registry |
| Q41972324 | The in vitro influences of epidermal growth factor and heregulin-β1 on the efficacy of trastuzumab used in Her-2 positive breast adenocarcinoma |
| Q34155601 | Translating research into evidence-based practice: the National Cancer Institute Community Clinical Oncology Program |
| Q85110839 | Trastuzumab Cardio-Oncology: Lessons Learned |
| Q38974785 | Trastuzumab cardiotoxicity: from clinical trials to experimental studies |
| Q24200192 | Trastuzumab containing regimens for early breast cancer |
| Q81967926 | Trastuzumab in early-stage breast cancer: the question of treatment timing |
| Q43065085 | Trastuzumab in the adjuvant setting: concurrent or sequential? It takes two to tango! |
| Q34484185 | Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. |
| Q44988976 | Trastuzumab use in breast cancer patients in the six Health Care Regions in Sweden |
| Q39163356 | Trastuzumab-associated cardiac events in the Persephone trial |
| Q37766549 | Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer |
| Q31004660 | Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data |
| Q54705428 | Trastuzumab-related cardiac events in the treatment of early breast cancer. |
| Q37289617 | Trastuzumab-related cardiotoxicity among older patients with breast cancer |
| Q37038459 | Trastuzumab-related cardiotoxicity in early breast cancer: a cohort study |
| Q58614608 | Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors |
| Q37682882 | Trastuzumab: A review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer |
| Q43045832 | Trastuzumab: a cardiologist's perspective |
| Q37213758 | Trastuzumab: a pharmacoeconomic review of its use in early breast cancer |
| Q81295719 | Trastuzumab: possible publication bias |
| Q38594154 | Treatment of Breast Cancer in the Elderly |
| Q28081124 | Treatment of early-stage HER2+ breast cancer-an evolving field |
| Q36227614 | Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study |
| Q37772792 | Treatment strategy for HER2-positive breast cancer |
| Q38401605 | Tyrosine kinase-targeting drugs-associated heart failure |
| Q39759252 | Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence |
| Q38503419 | Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumab-related cardiac dysfunction: preclinical and clinical considerations |
| Q47893099 | Use of trastuzumab in Australia and New Zealand: results from the National Breast Cancer Audit |
| Q37797337 | What's new in neoadjuvant therapy for breast cancer? |
Search more.